Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 123-129

  Derache, Anne ^a   Traore, Ousmane ^b   Koita, Victoria ^b   Sylla, Aliou ^b,c   Tubiana, Roland ^a   Simon, Anne ^a   Canestri, Ana ^a   Carcelain, Guislaine ^a   Katlama, Christine ^a   Calvez, Vincent ^a   Cisse, Mamadou ^b   Marcelin, Anne Geneviève ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre d'Ecoute de Soins d'Animations et de Conseils   (Mali)

^c Cellule Multisectorielle de Lutte Contre le Sida   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALI; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MALI; MIDDLE AGED; MUTATION; PHYLOGENY; RNA, VIRAL; VARIATION (GENETICS);

EID: 33847377947     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000; 288:55-56
2. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71:8893-8898
3. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A 2002; 99:14410-14415
4. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925
5. Apetrei C, Descamps D, Collin G, et al. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol 1998; 72:3534-3538
6. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111
7. Parkin NT Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9:3-12
8. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997; 71:5441-5448
9. Perno CF, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184:983-991
10. Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux J. Suceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr 1992; 5:359-364
11. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991; 5:137-144
12. Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A 1998; 95:14441-14446
13. HIV Sequence Database [database on the internet]. Los Alamos National Laboratory [cited March 2006]. Available from: http://hiv-web.lanl.gov/content/ hiv-db/SUBTYPE_REF/align.html
14. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131
16. Stanford University HIV Drug Resistance Database [cited September 2006]. http://hivdb.stanford.edu/
17. Laurent C, Bourgeois A, Faye MA, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study. J Infect Dis 2002; 186:486-492
18. Mamadou S, Montavon C, Ben A, et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res Hum Retroviruses 2002; 18:723-726
19. Montavon C, Toure-Kane C, Liegeois F, et al. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000; 23:363-374
20. Montavon C, Toure-Kane C, Nkengasong JN, et al. CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and J. J Acquir Immune Defic Syndr 2002; 29:522-530
21. Sankale JL, Hamel D, Woolsey A, et al. Molecular evolution of human immunodeficiency virus type 1 subtype A in Senegal: 1988-1997. J Hum Virol 2000; 3:157-164
22. Toni TD, Recordon-Pinson P, Minga A, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 2003; 19:713-717
23. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552
24. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hunt Retroviruses 2003; 19:151-160
25. Petch LA, Hoffman IF, Jere CS, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses 2005; 21:799-805
26. Vidai N, Mulanga C, Bazepep SE, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006; 22:202-206
27. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180
28. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.